HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ulta’s Upgraded FY2022 Outlook A Good Sign For Holiday Beauty

Executive Summary

Ulta has increased its fourth quarter and fiscal 2022 full-year outlook on strong third-quarter comparable store sales growth of 14.5%. Mass beauty is outperforming prestige, but CEO David Kimbell said “it’s hard to know for certain if we are starting to see consumers trade down.”

You may also be interested in...



‘Lipstick Effect’ Holding In 2023 Despite Continuing Price Escalation – Catalina Marketing

Consumers continued to spend more on beauty products in January 2023 in US mass retail doors despite rising prices across face makeup, eye makeup and lipstick segments, according to market intelligence and consulting firm Catalina Marketing.

Consumers Cool On Holiday Spending With Doubts ‘Deep Discounts’ Are Coming

One likely reason for tighter spending plans is consumers aren’t expecting “deep discounts” offered in US earlier in 19 pandemic, shows Simon-Kucher survey. Four times as many than in 2021 expect 10% or less discounts.

Prestige Beauty Lines Ring In Holiday Season Riding Sales Growth, Reining In Price Increases

Prestige beauty sales should be strong through year-end with high-income consumer base less likely to feel squeeze of inflation, NPD Group forecasts. In 2022 first half, US consumers with more than $100,000 household incomes spent nearly $9bn on beauty products, a 14% increase.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel